Summary
Mycophenolate mofetil (the morpholinoethyl ester of mycophenolic acid) inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase. Its selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation. Mycophenolate mofetil has immunosuppressive effects alone, but is used most commonly in combination with other immunosuppressants. Mycophenolate mofetil, in combination with cyclosporin and corticosteroids, has been studied in large, randomised clinical trials involving nearly 1500 renal allograft transplant recipients. These trials demonstrated that mycophenolate mofetil is significantly more effective in reducing treatment failure and acute rejection episodes than placebo or azathioprine. Additionally, mycophenolate mofetil may be able to reduce the occurrence of chronic rejection.
Mycophenolate mofetil is relatively well tolerated. The most common adverse effect reported is gastrointestinal intolerance; haematological aberrations have also been noted. The reversible cytostatic action of mycophenolate mofetil allows for dose adjustment or discontinuation, preventing serious toxicity or an overly suppressed immune system. Cytomegalovirus tissue invasive disease and the development of malignancies are concerns that merit evaluation in long term follow-up studies.
Mycophenolate mofetil does not cause the adverse effects typically associated with other commercially available immunosuppressant medications such as nephrotoxicity, hepatotoxicity, hypertension, nervous system disturbances, electrolyte abnormalities, skin disorders, hyperglycaemia, hyperuricaemia, hypercholesterolaemia, lipid disorders and structural bone loss.
Based on preliminary information, a positive benefit-risk ratio has been demonstrated with the use of mycophenolate mofetil in the prophylaxis of rejection in cadaveric renal allograft transplantation. Data from studies in other types of organ transplants are promising, but are too limited to draw clear conclusions. Long term follow-up studies are required to confirm these observations. Although mycophenolate mofetil is expensive, the beneficial effects on the reduction of rejection, treatment failure and related expenses suggest that it is most likely to be cost effective.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Halloran PF. Rethinking immunosuppression in terms of the redundant and nonredundant steps in the immune response. Transplant Proc 1996 Dec; 28 (6) 1 Suppl.: 11–8
Florey HW, Gilliver K, Jennings MA, et al. Mycophenolic acid — an antibiotic from Penicillium brevicompactum. Lancet 1946; I: 46–9
Lee WA, Gu L, Miksztal AR, et al. Bioavailability improvement of mycophenolic acid through aminoester derivatization. Pharm Res 1990 Feb; 7 (2): 161–6
Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anti-cancer compound with unusual properties. Nature 1969 Aug 23; 223 (208): 848–50
Williams RH, Lively DH, Delong DC, et al. Mycophenolic acid: antiviral and antitumor properties. J Antibiot 1968 Jul; 21 (7): 463–4
Lynch WS, Roenigk Jr HH. Mycophenolic acid for psoriasis. Arch Dermatol 1977 Sep; 113 (9): 1203–8
Epinette WW, Parker CM, Jones EL, et al. Mycophenolic acid for psoriasis: a review of pharmacology, long term efficacy, and safety. J Am Acad Dermatol 1987 Dec; 17 (6): 962–71
Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993; 11 (8 Suppl.): 117–9S
Allison AC, Kowalski WJ, Muller CD, et al. Mechanisms of action of mycophenolic acid. Ann NY Acad Sci 1993; 696: 63–87
Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969 Jul; 113 (3): 515–24
Verham R, Meek TD, Hedstrom L, et al. Purification, characterization, and kinetic analysis of inosine 5′-monophosphate dehydrogenase of trichomonas foetus. Mol Biochem Parasitol 1987 May; 24(1): 1–12
Morris RE, Hoyt EG, Eugui EM, et al. Prolongation of rat heart allograft survival of RS61443. Surg Forum 1989; 40: 337–8
Platz KP, Sollinger HW, Hullett DA, et al. RS-61443: a new, potent immunosuppressive agent. Transplantation 1991 Jan; 51 (1): 27–31
Benhaim P, Anthony JP, Lin LY, et al. A long term study of allogeneic rat hind limb transplants immunosuppressed with RS-61443. Transplantation 1993 Oct; 56 (4): 911–7
O’Hair DP, McManus RA, Komorowski R. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 1994 Nov; 58(5): 1311–5
Allison AC, Eugui EM, Sollinger HW. Mycophenolate mofetil (RS-61443): mechanisms of action and effects in transplantation. Transplant Rev 1993 Jul; 7 (3): 129–39
Carr SF, Papp E, Wu JC, et al. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268: 27286–90
Lowe JK, Brox L, Henderson JF. Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole. Cancer Res 1977 Mar; 37 (3): 736–43
CellCept (mycophenolate mofetil) product information. June 1995, Hoffman-La Roche Inc., Nutley, NJ 07110–1199, USA
Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996 Apr; 28 (2): 925–9
Wu JC. Mycophenolate mofetil: molecular mechanisms of action. Perspect Drug Discovery Design 1994; 2: 185–204
Shaw LM, Sollinger HW, Halloran P, et al. Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit 1995; 17 (6): 690–9
Shaw LM, Nowak I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit 1995; 17 (6): 685–9
Parker G, Bullingham R, Kamm B, et al. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996 Apr; 36 (4): 332–41
Zucker K, Esquenazi V, Rosen A, et al. Unexpected augmentation of MMF pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy, and analogous in vitro findings [abstract]. International Congress of the Transplantation Society; 1996 Aug 25–30; Barcelona, 60
Eugui EM, Almquist S, Muller CD, et al. Lymphocyte selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991 Feb; 33 (2): 161–73
Grailer A, Nichols J, Hullett D, et al. Inhibition of human B-cell responses in vitro by RS-61443, cyclosporine A, and DAB486IL-2. Transplant Proc 1991 Feb; 23 (1): 314–5
Kimball JA, Pescovitz MD, Book BK, et al. Reduced human IgG anti-Atgam antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995 Dec 27; 60 (12): 1379–83
Dayton JS, Turka LA, Thompson CB, et al. Comparison of the effects of mizoribine with those of azathioprine 6-mercaptopurine and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1992 Apr; 41: 671–6
Morris RE, Hoyt EG, Murphy MP, et al. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T and B cell purine synthesis. Transplant Proc 1990 Aug; 22: 1659–62
Morris RE. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993 Nov–Dec; 12 (6 Pt 2): 275–86
Platz KP, Eckhoff DE, Bechstein WO, et al. RS-61443 for reversal of acute rejection in canine renal allografts. Surgery 1991 Oct; 110:736–41
Steele DM, Hullett DA, Bechstein WO, et al. Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 1993 Feb; 25 (1 Pt 1): 754–5
Langman LJ, Legatt DF, Halloran PF, et al. Pharmacodynamic assessment of mycophenolic acid induced immunosuppres-sion in renal transplant recipients. Transplantation 1996 Sep 15; 62 (5): 666–72
Sollinger HW, Deierhoi MH, Beizer FO, et al. RS-61443: a phase I clinical trial and pilot rescue study. Transplantation 1992 Feb; 53 (2): 428–32
Sollinger HW, Beizer FO, Deierhoi MH, et al. RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg 1992 Oct; 216 (4): 513–9
European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995 May 27; 345: 1321–5
Gonwa TA. Mycophenolate mofetil for maintenance therapy in kidney transplantation. Clin Transplant 1996; 10: 128–30
Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renaltransplantation. Transplantation 1996 Apr 15; 61 (7): 1029–37
Sollinger HW, U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995 Aug 15; 60 (3): 225–32
Sollinger HW, Update on preclinical and clinical experience with mycophenolate mofetil. Transplant Proc 1996 Dec; 28 (6) Suppl. 1: 24–9
Cecka JM. Early rejection: determining the fate of renal transplants. Transplant Proc 1991 Feb; 23 (2 Pt 1): 1263–4
Naimark DM, Cole E. Determinants of long term renal allograft survival. Transplant Rev 1994 Jul; 8 (3): 93
Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993 May; 55: 933–5
Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996 Mar 15; 61 (5): 722–9
Morris RE, Wang J, Blum JR, et al. Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and non-human primate recipients of heart allografts. Transplant Proc 1991 Apr 23; Suppl. 2: 19–25
Hullett DA, Kawamura T, Fujino Y, et al. Prolongation of allograft and xenograft survival with mycophenolate mofetil (RS-61443) and brequinar sodium (DUP-785). Transplant Proc 1993 Feb; 25 (1): 700–1
Yatscoff RW, Wang S, Keenan R. Efficacy of rapamycin, RS-61443 and cyclophosphamide in the prolongation of survival of discordant pig-to-rabbit cardiac xenografts. Transplant Proc 1994 Jun; 26 (3): 1271–3
Murase N, Starzl TE, Demetris AJ, et al. Hamster-to-rat heart and liver xenotransplantation with FK 506 plus antiproliferation drugs. Transplantation 1993 Apr; 55: 701–8
Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart recipients. Transplantation 1993 Jul; 56 (1): 75–82
Kirklin J, Bourge RC, Naftel DC, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994 May–Jun; 13 (3): 444–50
Renlund DG, Gopinathon SK, Kfoury AG, et al. Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Clin Transplant 1996; 10: 136–9
Bechstein WO, Schilling M, Steele DM, et al. RS-61443/ cyclosporine combination therapy prolongs canine liver allograft survival. Transplant Proc 1993 Feb; 25 Pt 1: 702–3
Klintmalm GB, Ascher NL, Busuttil RW, et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993 Feb; 25: 697
Freise CE, Hebert M, Osorio RW, et al. Maintenance immuno-suppression with prednisone and RS-61443 alone following liver transplant. Transplant Proc 1993 Apr; 25 (2): 1758–9
Hebert M, Lake J, Linna TJ, et al. Mycophenolate mofetil for prophylaxis against rejection following orthotopic liver transplantation [abstract]. 15th World Congress of the Transplantation Society; 1994 Aug 28–Sep 2; Kyoto, 343
Hao L, Lafferty AJ, Allison AC, et al. RS-61443 allows islet allografting and specific tolerance in adult mice. Transplant Proc 1990 Apr; 22: 876–9
Qi S, Chen H, Xu D, et al. Prolongation of pancreas allograft survival by mycophenolate mofetil in the rat. Transplant Proc 1996 Apr; 28 (2): 932–3
Stegall MD, Simon M, Wachs M, et al. Decreased rejection in simultaneous pancreas-kidney (SPK) transplantation with mycophenolate mofetil (MM): a randomized trial of tacrolimus and cyclosporine [abstract]. American Society of Transplant Physicians 15th Annual Meeting; 1996 May 26–29; Dallas
D’alessandro AM, Rankin M, McVey J, et al. Prolongation of canine intestinal allograft survival with RS-61443, cyclosporine and prednisone. Transplantation 1993 Apr; 55 (4): 695–701
Lewis RL, Canafax DM, Pettit KG, et al. Use of Markov modeling for evaluating the cost-effectiveness of immunosuppressive therapies in renal transplant recipients. Transplant Proc 1996 Aug; 28 (4): 2214–7
Danovitch GM, editor. Handbook of kidney transplantation. New York: Little, Brown and Company, 1996
Louis-Touizer C, Nuijten MJ, Bayle F, et al. Economic contribution of mofetil mycophenolate as preventive immunosuppressive treatment after renal transplantation from cadaver. Presse Med 1996 Nov 2; 25 (33): 1577–82
McEvoy GK, editor. American Hospital Formulary Service Drug Information. Bethesda: American Society of Health-System Pharmacists, 1997
Aroldi A, Tarantino A, Montagnino G, et al. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients. Transplantation 1997 Feb; 63 (3): 380–6
Cvetkovic M, Mann G, Romero D, et al. The deleterious effects of long-term cyclosporin A, cyclosporin G and FK506 on bone mineral metabolism in vivo. Transplantation 1994 Apr; 57 (8): 1231–7
Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem 1996; 42 (8B): 1316–21
Steinmuller DR. Cyclosporine nephrotoxicity. Cleve Clin J Med 1989; 56: 89–95
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Simmons, W.D., Rayhill, S.C. & Sollinger, H.W. Preliminary Risk-Benefit Assessment of Mycophenolate Mofetil in Transplant Rejection. Drug-Safety 17, 75–92 (1997). https://doi.org/10.2165/00002018-199717020-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199717020-00001